Wang Z, Luo F, Jiang S, Selvaraj JN, Zhou Y, Zhang G (2023d) Biochemical characterization and molecular modification of a zearalenone hydrolyzing enzyme Zhd11D from Phialophora attinorum
In a 4-year CV outcomes trial (Trial 7), 4,825 patients were randomized to RYBELSUS for a median follow-up of 49.6 months and 4,825 patients were randomized to placebo for a median follow-up of 49.4 months [see Clinical Studies (14.4)]
Bone and connective tissue healing also benefits from GHK-Cu
Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway
"What hasn't been even described or reported in the peer-reviewed medical literature is what does maintenance on these medications look like," Ashton said, adding, "That knowledge and awareness has to be there, that if you get to your goal weight, and you completely stop these medications, the vast majority, not all, but the vast majority of people will regain the weight that's lost." Ashton said patients on a medication like Wegovy should work closely with their doctor determine what is best in their individual situation
This was a great article